What is Aviscera Bioscience?
Aviscera Bioscience operates as a high-authority supplier of specialty proteins, specifically focusing on Adipokines, Myokines, and Cytokines. These biological markers are essential for advancing research into Metabolic Syndrome and Cardiovascular Diseases. By providing high-purity reagents and diagnostic tools, the company serves as a critical infrastructure partner for academic institutions and pharmaceutical entities engaged in complex therapeutic discovery. Their market position is defined by a commitment to precision in protein synthesis, which facilitates the translation of basic research into viable clinical applications for chronic health conditions.
How much funding has Aviscera Bioscience raised?
Aviscera Bioscience has raised a total of $21K across 1 funding round:
Debt
$21K
Debt (2021): $21K with participation from PPP
Key Investors in Aviscera Bioscience
PPP
Public-Private Partnership
What's next for Aviscera Bioscience?
Following this significant Series B/C stage financing, Aviscera Bioscience is well-positioned to scale its operational capacity and broaden its product portfolio. The strategic deployment of this capital will likely focus on enhancing manufacturing throughput and accelerating the development of novel biomarkers that address unmet needs in cardiovascular health. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward expanding its commercial footprint and deepening its integration into the global drug discovery pipeline. This investment serves as a catalyst for sustained innovation, enabling the firm to maintain its competitive edge in the high-barrier-to-entry biotechnology market.
See full Aviscera Bioscience company page
